Pfizer Ltd. (NSE: PFIZER), India's 13th largest Pharmaceuticals company by market cap, has increased Rs65.50 (1.6%) from its previous trading session to close at Rs4,074.05. Compared with the BSE SENSEX Index which rose 136.9 p...
Nifty Midcap down 25% from Jan 2018 highs; but these 15 stocks rallied 20-135% Experts expect most of the midcaps, as well as, the smallcaps to rally and even to outperform the largecaps, albeit not immediately.
Market Headstart: Nifty likely to open higher; Voltas, Pfizer top buy ideas Experts expect Nifty to be volatile amid F&O expiry but if the index breaks 11,382, the crucial support level, then the selling could intensify in coming sessions.
Market Headstart: Nifty likely to open higher; Voltas, Pfizer top buy picks Experts expect Nifty to be volatile amid F&O expiry but if the index breaks 11,382, the crucial support level, then the selling could intensify in coming sessions.
Biocon subsidiary acquires research facility from Pfizer Healthcare Biocon Biologics has acquired research and development (R&D) capital assets of a 60,000-square feet research facility at Ticel Bio Park in Chennai, Biocon said in a statement.
What are allowances and which allowances are exempt? Allowance is defined as a fixed quantity of money or other substance given regularly in addition to salary for meeting specific requirements of the employees.
Stocks in the news: Axis Bank, Hero Moto, Tech Mahindra, DHFL, JSW Steel, Gujarat Gas, Alkem Tech Mahindra | DHFL | JSW Steel | Gujarat Gas | Alkem Labs | Dish TV | Shoppers Stop and Vinati Organics are stocks which are in the news today.
Pfizer’s Upjohn-Mylan merger may have little impact on India operations As part of the Upjohn-Mylan deal, the Indian unit of US drug major Pfizer announced on July 30 that it will be transferring six brands to the combined entity.
This week in Pharma: Potential Pfizer-Mylan deal could begin consolidation of generic industry The combined entity after the merger of Pfizer’s off-patent business and Mylan would become the largest generic drug maker globally, and may set the pace for the consolidation of an industry facing pricing pressure amidst competition and channel consolidation in US market.